

APTACHEM

Malmö July 20, 2018

PRESS RELEASE

Yorkville Advisors Global subscribe for 99 502 shares in Aptahem by converting convertibles

On 26 June 2018, Aptahem (publ) signed an issuance agreement with YA II PN Ltd, a fund represented by the United States-based Yorkville Advisors Global ("Yorkville"), which describes the terms of issuance of and subscription to notes convertible into new shares in Aptahem (the "Yorkville Agreement").

The first tranche of 25 convertibles under the Yorkville Agreement was issued by Aptahem's board on 26 June 2018 for a total value of SEK 2.5 million. On July 17, 2018, Yorkville called for conversion of two of these convertibles for subscription of 99,502 shares in Aptahem. The conversion price per share amounts to SEK 2.01, which corresponds to 90% of the lowest daily volume weighted average price for Aptahem's share over the five trading days prior to the date of conversion. Through the conversion, the company's share capital increases by SEK 22,614.091 SEK to 3,568,878.6508 SEK and the number of shares in the company increases by 99,502 to 15,703,066.

For further information:

Mikael Lindstam, CEO, Aptahem AB

Tel: + 46 (0)766-33 36 99

E-mail: ml@aptahem.com

This information is information that Aptahem AB is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on July 20, 2018.

Forward-looking statements

This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

About Aptahem

Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company's primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.